<DOC>
	<DOC>NCT00083889</DOC>
	<brief_summary>The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).</brief_summary>
	<brief_title>SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically confirmed renal cell carcinoma of clear cell histology with metastases Evidence of measurable disease by radiographic technique Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1 Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC History of or known brain metastases Serious acute or chronic illness or recent history of significant cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>